Notice of Intent to Sole Source for Mycoplasma Testing

The Centers for Disease Control and Prevention Reagent and Diagnostics Serice Branch intends to award a sole source firm-fixed price purchase order to Bionique Testing Laboratories for rapid RT-PCR testing for low levels of Mycoplasma contaminants (1-10 genomic copies), generation of growth curves by enrichment for sensitivity, and pan-species detection for the dozens of Mycoplasma species that could contaminate CDC’s 25 mammalian cell culture lines in weekly production and hybridoma lines that have never been tested prior. Bionique PCR technology replaces time-consuming, subjective in-house testing with consistency and certificates of analysis under pending GMP regulation. This fulfills the cell culture and hybridoma needs of DSR and growing list of projects developed from CDC SMEs.

This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) and 41 U.S.C. 3304(a)(1)…. Interested persons may identify their interest and capability to respond to the requirement or submit proposals.

This notice of intent is not a request for competitive quotations; however, all quotations/responses received within Seven (7) days of the issuance of this notice will be considered by the Government.  A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government.  Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.  Any quotation/response should be emailed to the Contract Specialist at pyx7@cdc.gov by COB 12 March 2021.